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Pulmonary arterial hypertension (PAH) is a heterogeneous disorder associated with a
progressive increase in pulmonary artery resistance and pressure. Although various
therapies have been developed, the 5-year survival rate of PAH patients remains low.
There is thus an important need to identify novel genes that are commonly dysregulated
in PAH of various etiologies and could be used as biomarkers and/or therapeutic targets.
In this study, we performed comparative transcriptome analysis of five mammalian PAH
datasets downloaded from a public database. We identified 228 differentially expressed
genes (DEGs) from a rat PAH model caused by inhibition of vascular endothelial
growth factor receptor under hypoxic conditions, 379 DEGs from a mouse PAH model
associated with systemic sclerosis, 850 DEGs from a mouse PAH model associated with
schistosomiasis, 1598 DEGs from one cohort of human PAH patients, and 4260 DEGs
from a second cohort of human PAH patients. Gene-by-gene comparison identified four
genes that were differentially upregulated or downregulated in parallel in all five sets of
DEGs. Expression of coiled-coil domain containing 80 (CCDC80) and anterior gradient
two genes was significantly increased in the five datasets, whereas expression of SMAD
family member six and granzyme A was significantly decreased. Weighted gene co-
expression network analysis revealed a connection between CCDC80 and collagen type
I alpha 1 (COL1A1) expression. To validate the function of CCDC80 in vivo, we knocked
out ccdc80 in zebrafish using the clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 system. In vivo imaging of zebrafish expressing a fluorescent
protein in endothelial cells showed that ccdc80 deletion significantly increased the
diameter of the ventral artery, a vessel supplying blood to the gills. We also demonstrated
that expression of col1a1 and endothelin-1 mRNA was significantly decreased in the
ccdc80-knockout zebrafish. Finally, we examined Ccdc80 immunoreactivity in a rat PAH
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model and found increased expression in the hypertrophied media and adventitia of the
pre-acinar pulmonary arteries (PAs) and in the thickened intima, media, and adventitia
of the obstructed intra-acinar PAs. These results suggest that increased expression of
CCDC80 may be involved in the pathogenesis of PAH, potentially by modulating the
expression of endothelin-1 and COL1A1.
Keywords: pulmonary arterial hypertension, comparative transcriptome analysis, weighted gene co-expression
network analysis, CCDC80, EDN1, COL1A1, systems pharmacology
INTRODUCTION
Pulmonary arterial hypertension is a progressive disease
characterized by increased pulmonary vascular resistance due to
vasoconstriction and remodeling (reviewed in Pullamsetti et al.,
2014; McLaughlin et al., 2015). The pathologic abnormalities in
vascular lesions include intimal hyperplasia, medial thickness,
plexiform lesions, and thrombosis in situ (Iwashita et al., 2014;
Otsuki et al., 2015; Shinohara et al., 2015), which are caused by
increased migration and proliferation of smooth muscle cells and
adventitial fibroblasts, abnormal endothelial cell proliferation,
and impaired apoptosis. Although several treatment options have
become available and have significantly improved morbidity and
mortality, the 5-year survival rate for PAH patients remains
at ∼60% (Korsholm et al., 2015). Early diagnosis and accurate
prognostic stratification of patients at baseline and during
follow-up are important to ensure optimal therapeutic strategies
(Pezzuto et al., 2015). Thus, finding novel genes involved in the
pathogenesis of PAH could provide a better understanding of the
pathophysiological mechanisms and suggest novel therapeutic
approaches for the disease (Guignabert et al., 2015; Machado
et al., 2015).
Transcriptome analysis could represent a new frontier in the
search for novel biomarkers and/or therapeutic targets in various
diseases, because it facilitates the identification of panels of genes
specifically dysregulated in affected tissues (Nishimura et al.,
2007, 2015b; Oldham et al., 2008; Oka et al., 2010; Sasagawa
et al., 2016). A number of transcriptome analyses of PAH patients
and PAH animal models have been performed and the data have
been deposited in a public database (Barrett et al., 2009). These
include data derived from two cohorts of human patients (Mura
et al., 2012; Zhao Y. et al., 2014; Zhao Y.D. et al., 2014); a rat
PAH model caused by treatment with the vascular endothelial
growth factor receptor inhibitor SU5416 under conditions of
hypoxia (Moreno-Vinasco et al., 2008); a mouse PAH model
caused by overexpression of Fra-2 (Biasin et al., 2014), a causative
gene for systemic sclerosis; a mouse PAH model caused by
schistosomiasis (Graham et al., 2013); a rat model caused by left
heart disease (Hoffmann et al., 2011); a rat model caused by
Pneumocystis infection (Swain et al., 2014); and a mouse PAH
model caused by deletion of cavin-1 (Swärd et al., 2013). In this
study, we sought to identify genes commonly dysregulated in
PAH in both human and rodent models. Therefore, we selected
Abbreviation: DEGs, differentially expressed genes; dpf, days post-fertilization;
ECM, extracellular matrix.; L-NAME, N-omega-nitro-L-arginine methyl ester;
PAH, pulmonary artery hypertension; PKG, cGMP-dependent protein kinase; SNP,
sodium nitroprusside.
for analysis both cohorts of human PAH patients (Mura et al.,
2012; Zhao Y. et al., 2014; Zhao Y.D. et al., 2014); two mouse
models caused by schistosomiasis (Graham et al., 2013) and
Fra-2 overexpression (Biasin et al., 2014), which were selected
because schistosomiasis and connective tissue diseases such as
systemic sclerosis are major causes of PAH (Simonneau et al.,
2013); and a rat PAH model caused by SU5416 and hypoxia
(Moreno-Vinasco et al., 2008), which we included in this study
because we have successfully employed this PAH model (Otsuki
et al., 2015; Shinohara et al., 2015). We acknowledg that our
transcriptome analysis of these datasets may not detect genes
involved in other common causes of PAH, such as left heart
and/or lung diseases.
We performed a comparative transcriptome analysis of the
two human and three rodent PAH datasets and found that
coiled-coil domain containing 80 (CCDC80) may be a novel
biomarker and therapeutic target in PAH. We validated the
function of CCDC80 as it relates to PAH using zebrafish.
Many transgenic zebrafish lines expressing fluorescent proteins
in various cells have been developed and are available through
public resources, enabling multiple approaches to in vivo imaging
of the relevant target cells in zebrafish larvae (Nishimura
et al., 2015a). Specific genes can also be knocked out
using clustered regularly interspaced short palindromic repeats
(CRISPR)-Cas9 systems (Auer and Del Bene, 2014). Thus, when
used in combination with advanced technologies for genetic
manipulation, in vivo imaging of the zebrafish ventral artery,
which supplies blood to the gill arches where gas exchange
occurs by diffusion (Jonz and Nurse, 2008), may be a useful
tool to characterize the function of genes related to PAH.
Our in vivo validation using the zebrafish model revealed that
ccdc80 knockout increased the diameter of the ventral artery.
Finally, we examined Ccdc80 expression in a rat PAH model
and found increased staining in the hypertrophied media and
adventitia of the pre-acinar pulmonary arteries (PAs) and in
the thickened intima, media, and adventitia of the obstructed
intra-acinar PAs.
MATERIALS AND METHODS
Ethics Statement
This study was carried out in strict accordance with Japanese
law [The Humane Treatment and Management of Animals
(2014), Standards Relating to the Care and Management of
Laboratory Animals and Relief of Pain (2013), and the Guidelines
for Proper Conduct of Animal Experiments (2006) (Science
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Council of Japan, 2006; Ministry of the Environment Japan,
2013, 2014)]. All efforts were made to minimize animal suffering.
Mie University Institutional Animal Care and Use Committee
guidelines state that no approval is required for experiments
using zebrafish.
Compounds
Sodium nitroprusside (SNP) was obtained from Millipore
(Billerica, MA, USA) and dissolved in 0.3x Danieau’s solution
(19.3 mM NaCl, 0.23 mM KCl, 0.13 mM MgSO4, 0.2 mM
Ca(NO3)2, 1.7 mM HEPES, pH 7.2) immediately before use
in experiments. KT5823 was obtained from Tocris (Bristol,
UK). Stock solutions of KT5823 were prepared by dissolving
in dimethyl sulfoxide (Nacalai Tesque, Kyoto, Japan). L-NAME
was obtained from Dojin Chemicals (Kumamoto, Japan).
2-Phenoxyethanol was obtained from Wako Chemicals (Osaka,
Japan).
Comparative Transcriptome Analysis
To compare DEGs in human PAH and rodent models of PAH of
different etiologies, we analyzed five lung transcriptome datasets.
GSE8078 was derived from a rat PAH model caused by treatment
with the VEGF receptor inhibitor SU5416 under conditions of
hypoxia (Moreno-Vinasco et al., 2008). Adult male rats received
a single subcutaneous injection of SU-5416 and were housed
under hypoxic condition for 3.5 weeks. mRNA was isolated from
whole lung tissue of the PAH rats (n = 3) and the control rats
(n= 4). GSE51222 was derived from a mouse PAH model caused
by overexpression of Fra-2 (Biasin et al., 2014), and mRNA was
isolated from the lung homogenates of 8-week-old transgenic
mice (n= 3) and wild-type littermate controls (n= 3). GSE48936
was derived from a mouse PAH model caused by schistosomiasis
(Graham et al., 2013). Female mice received an intraperitoneal
injection of Schistosoma mansoni eggs followed 2 weeks later by
challenge with S. mansoni eggs injected via the tail vein. One
week later, lung mRNA was isolated from injected (n = 3) and
uninjected (n = 3) mice. GSE24988 and GSE53408 were derived
from human PAH patients (Mura et al., 2012; Zhao Y. et al.,
2014; Zhao Y.D. et al., 2014). For our study, we compared the
transcriptomes of patients with pulmonary fibrosis without PAH
(n = 22) and with intermittent PAH (n = 45) in GSE24988 and
controls (n= 11) and patients with PAH (n= 12) in GSE53408.
The raw data were normalized using the packages “affy”
(Gautier et al., 2004) for GSE8078, “limma” (Ritchie et al.,
2015) for GSE51222, and “oligo” (Carvalho and Irizarry, 2010)
for GSE48936, GSE24988, and GSE53408 in Bioconductor
(Gentleman et al., 2004). Probes with reliable signals were
selected and subjected to RankProd (Breitling et al., 2004)
analysis to identify DEGs in the PAH groups compared with
control groups in each dataset. False discovery rates were set at
20% for the rodent PAH models, 10% for one human cohort
(GSE24988), and 5% for the second human cohort (GSE53408).
The gene symbols of the DEGs were converted to the human
orthologs using Life Science Knowledge Bank (World Fusion,
Tokyo, Japan), and UniProt IDs were added using the ID
mapping tool (UniProt Consortium, 2015). The lists of DEGs are
shown in Supplementary Tables S1-1–S1-5. The DEGs common
to all five PAH transcriptome datasets are shown in Table 1.
Weighted Gene Co-Expression Network
Analysis
To identify molecular interactions between genes potentially
related to PAH, we performed weighted gene co-expression
network analysis (WGCNA). WGCNA can organize
transcriptomic data into networks based on underlying
expression relationships, such as correlations, to elucidate novel
connections between genes (Oldham et al., 2008). Expression
data for 40 genes commonly dysregulated in the five PAH
transcriptome datasets (Supplementary Table S2) were subjected
to WGCNA (Langfelder and Horvath, 2008) in Bioconductor
(Gentleman et al., 2004). The 40 genes were clustered into
three modules of correlated genes: the first contained CCDC80,
the second contained both SMAD6 and GZMA, and the third
contained AGR2. The gene networks in modules 1, 2, and 3 were
identified using thresholds of 0.05, 0.25, and 0.02, respectively.
Zebrafish Strains
We used two lines of zebrafish: a Tg (fli1:EGFP) line (Lawson and
Weinstein, 2002) obtained from Zebrafish International Resource
Center (Eugene, OR, USA) (Varga, 2011) and an albino line
(Kelsh et al., 1996) obtained from the Max Planck Institute for
Developmental Biology (Tübingen, Germany). Zebrafish were
bred and maintained according to previously described methods
(Westerfield, 2007; Nishimura et al., 2016). Briefly, zebrafish were
raised at 28.5◦C ± 0.5◦C with a 14 h/10 h light/dark cycle.
Embryos were obtained by natural mating and cultured in 0.3x
Danieau’s solution until 6 dpf, at which time they were used for
the in vivo imaging analyses or were processed for quantitative
polymerase chain reaction (qPCR).
Knockout of ccdc80 in Zebrafish
Knockout of ccdc80 in zebrafish was performed by the ready-
to-use CRISPR/Cas9 method (Kotani et al., 2015). CRISPR
RNA (crRNA) targeting a 5′-AAGCAGCCCGACCGATAAAC-3′
sequence in the ccdc80 genome and trans-activating crRNA
(tracrRNA; Kotani et al., 2015) were obtained from FASMAC
(Kanagawa, Japan). Recombinant Cas9 protein was obtained
from Toolgen (Seoul, South Korea). In brief, crRNA, tracrRNA,
and Cas9 protein were dissolved in sterilized water at
concentrations of 250, 1000, and 1000 ng/µl, respectively,
and stored at −80◦C until required. For microinjection, the
crRNA, tracrRNA, Cas9 protein, and a lissamine-labeled control
morpholino with no known target gene (Gene Tools, Philomath,
OR, USA) were mixed in Yamamoto’s Ringer’s solution (0.75%
NaCl, 0.02% KCl, 0.02% CaCl2, 0.002% NaHCO3) to final
concentrations of 100 ng/µl, 100 ng/µl, 400 ng/µl, and 50 nM,
respectively. The solution was injected into 1–4-cell-stage
zebrafish embryos derived from the Tg (fli1: EGFP) line or
albino lines. At 1 dpf, the embryos exhibiting bright lissamine
fluorescence were selected and maintained until 6 dpf. At 6 dpf,
the selected zebrafish were used for in vivo imaging of the ventral
artery or were processed for qPCR. After completion of the in vivo
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TABLE 1 | Differentially expressed genes common to the five PAH transcriptome datasets.
SU5416/hypoxia
GSE8078
Fra-2 TG
GSE51222
Schistosomiasis
GSE48936
Human PAH
GSE24988
Human PAH
GSE53408
Symbol UniProt ID log (PAH/C) FDR log (PAH/C) FDR log (PAH/C) FDR log (PAH/C) FDR log (PAH/C) FDR
AGR2 095994 1.17 0.01 0.87 0.01 1.26 0.03 0.35 0.00 1.19 0.00
CCDC80 Q76M96 0.71 0.14 0.61 0.06 1.02 0.08 0.17 0.00 1.15 0.00
GZMA P12544 –0.61 0.06 –4.18 0.00 –0.77 0.17 –0.16 0.04 –0.71 0.00
SMAD6 043541 –1.12 0.00 –0.51 0.16 –1.18 0.03 –0.03 0.10 –0.96 0.00
imaging experiments, genomic DNA was extracted from the
zebrafish by incubation in 50 µl of lysis buffer (10 mM Tris-HCl,
pH 8.0, 0.1 mM EDTA, 0.2% Triton X-100, 200 µg/ml proteinase
K) at 55◦C overnight, followed by incubation at 99◦C for 10 min.
The solution was then placed at 4◦C and used as the template
for PCR. To detect the crRNA-induced mutations, a short
fragment of the ccdc80 gene encompassing the crRNA target
sites was amplified from the genomic DNA using ccdc80_gF1
and ccdc80_gR1 primers and QuickTaq (Toyobo, Osaka, Japan).
PCR cycling conditions were: 94◦C for 2 min followed by 40
cycles of 94◦C for 30 s, 60◦C for 30 s, and 68◦C for 30 s. The
PCR products were electrophoresed on 10% poly-acrylamide gel
(Wako Chemicals) and visualized by ethidium bromide staining.
The crRNA, tracrRNA, and PCR primer sequences are shown in
Supplementary Table S3.
In Vivo Imaging of the Ventral Artery of
Tg (fli1:EGFP) Zebrafish
Zebrafish at 6 dpf were incubated with or without SNP (1–
10 mM) and/or L-NAME (10 mM) in the presence or absence of
the protein kinase G (PKG) inhibitor KT5823 (1 µM). Zebrafish
were exposed to the chemicals for 1 h for experiments examining
the SNP dose-response and the effect of KT5823, and for 2 h for
the experiments examining the effect of L-NAME with or without
SNP. The zebrafish were then transferred onto glass slides, placed
on their backs, and immobilized by covering with a few drops
of 3% low-melting point agarose solution. The ventral artery was
visualized using an epifluorescence microscope (SMZ25, Nikon,
Tokyo, Japan) with GFP-B filters, and images were recorded
at 100 frames/s for 5 s. Quantitative assessment of the ventral
artery diameter was performed using Volocity (Perkin Elmer,
Cambridge, MA, USA). Briefly, the time-lapse images were used
to generate M-mode tracings at the level immediately below the
first branches of the ventral artery. The ventral artery diameters
were then measured manually. The lengths of ventral artery
(from the level immediately below the bifurcation to 1st afferent
branchial artery to the level immediately above arterial bulb) were
also measured manually.
qPCR Analysis
Total RNA was extracted from control or ccdc80-KO albino
zebrafish at 6 dpf using an RNAqueous Micro Kit (Takara,
Kyoto, Japan) according to the manufacturer’s protocol.
RNA concentrations were determined using a NanoDrop
spectrophotometer (Thermo Scientific, Waltham, MA, USA),
and aliquots were reverse transcribed using an iScript Select
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). qPCR
was performed using an ABI Prism 7300 (Life Technologies,
Carlsbad, CA, USA) with SYBR Green Realtime PCR Master
Mix Plus (Toyobo). The thermal cycling conditions were:
95◦C for 1 min followed by 40 cycles of 95◦C for 15 s, 60◦C
for 15 s, and 72◦C for 45 s. We measured the expression of
collagen type I alpha 1 (col1a1), secreted frizzled-related protein
2 (sfrp2), endothelin-1 (edn1), and glyceraldehyde-3-phosphate
dehydrogenase (gapdh) mRNA. The data were normalized
to gapdh mRNA levels to correct for variability in the initial
template concentration and the conversion efficiency of the
reverse transcription reaction. The primer sequences are shown
in Supplementary Table S3.
Immunohistochemistry
Immunohistochemistry was performed as described previously
on lungs excised from control rats or rats with PAH
caused by SU5416/hypoxia (Otsuki et al., 2015; Shinohara
et al., 2015). Briefly, sections of paraffin-embedded lung
tissue were deparaffinized and hydrated. Epitope retrieval was
performed by boiling the sections in citrate buffer (0.01 M,
pH 6.0), and endogenous peroxidase activity was quenched
with 0.3% hydrogen peroxide in methanol. Sections were then
blocked in 5% normal goat serum and incubated overnight
at 4◦C with a rabbit polyclonal antibody to Ccdc80 (ab75881,
Abcam, Cambridge, UK) or a mouse monoclonal antibody to
α-smooth muscle actin (α-SMA, 1A4; Sigma, St. Louis, MO,
USA). Antibody binding was amplified with streptavidin-biotin
(LSAB2 kit, Dako, Kyoto, Japan), and sections were incubated
with 3,3′-diaminobenzidine substrate and counterstained with
hematoxylin. For the negative controls, sections were incubated
with rabbit or mouse immunoglobulin instead of the primary
antibody (Figures 5D,H). The localization and intensity of
staining were assessed by two independent examiners (HS and
EZ) who were blinded to the rat treatment group.
Statistical Analysis
Statistical analysis was performed using Prism 6 (GraphPad,
La Jolla, CA, USA). Group means were compared by unpaired
t-test for two groups and by analysis of variance (ANOVA)
for four groups. Alpha was set at 0.05, and Dunnett’s multiple
comparisons test was used for post hoc analysis when significant
effects were found by ANOVA. Data are shown as the
mean± standard error (SEM).
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RESULTS
Identification of DEGs Common to the
Five Mammalian PAH Transcriptome
Datasets
We performed comparative transcriptome analysis to identify
genes dysregulated in the three rodent PAH models and two
cohorts of human PAH patients. We identified 228, 379, 850,
1598, and 4260 DEGs in PAH caused by SU5416/hypoxia, Fra-
2 TG, schistosomiasis, human PAH cohort 1, and human PAH
cohort 2, respectively, compared with the relevant controls
(Supplementary Tables S1-1–S1-5). A Venn diagram showing
unique and shared DEGs is shown in Figure 1. Four DEGs were
either upregulated or downregulated in all five datasets (Table 1).
Expression of coiled-coil domain containing 80 (CCDC80) and
anterior gradient 2 (AGR2) was significantly increased in the five
PAH transcriptome datasets, whereas SMAD family member 6
(SMAD6) and granzyme A (GZMA) were significantly decreased
in all datasets. These results suggest that the four DEGs may be
novel biomarkers in PAH.
Identification of Gene Networks
Dysregulated in PAH
To identify molecular networks common to the genes
dysregulated in PAH, we used WGCNA. We calculated the
coefficient of variation (CV) of the normalized probe intensity
for each gene in each transcriptome dataset and then sorted
the genes in descending order by CV. The top 3000 genes in
FIGURE 1 | Venn diagram of DEGs in the five PAH transcriptome datasets. Transcriptome data from a rat PAH model caused by treatment with the VEGFR
inhibitor SU5416 and hypoxia (GSE8078); a mouse PAH model caused by overexpression of Fra-2, a causative gene for systemic sclerosis (GSE51222); a mouse
PAH model caused by schistosomiasis (GSE48936); and two cohorts of human PAH patients (GSE24988 and GSE53408) were downloaded from a public database
(GEO). Genes that were differentially expressed in the PAH and control groups of each dataset were identified as described in the methods. The numbers of DEGss
unique to each transcriptome dataset and shared between datasets are shown.
Frontiers in Pharmacology | www.frontiersin.org 5 June 2016 | Volume 7 | Article 142
fphar-07-00142 June 6, 2016 Time: 17:58 # 6
Sasagawa et al. Involvement of CCDC80 in PAH
each PAH transcriptome dataset were selected (Supplementary
Tables S1-1–S1-5). A total of 40 genes were common to the five
sets of 3000 genes (Supplementary Tables S2-3–S2-6) and were
subjected to WGCNA. Figure 2 shows the networks assigned
to the genes dysregulated in PAH by WGCNA. The four genes
identified in Table 1 (CCDC80, AGR2, SMAD6, and GZMA) are
included in the three networks identified by WGCNA (Figure 2).
CCDC80 is connected to collagen type I alpha 1 (COL1A1),
secreted frizzled-related protein 2 (SFRP2), and insulin-like
growth factor 1 (IGF1). SMAD6 is connected to endothelin 1
(EDN1) and GZMA. COL1A1, IGF1, and EDN1 have all been
associated with the pathophysiology of PAH (Ooi et al., 2010;
Pullamsetti et al., 2014; Madonna et al., 2015; McLaughlin et al.,
2015), supporting our hypothesis that CCDC80, SMAD6, and
GZMA may be involved in the disease pathophysiology.
Nitric Oxide Induces Ventral Artery
Dilation Through Activation of PKG in
Zebrafish
Although comparative transcriptome analysis identified CCDC80
as a novel gene in PAH, the function of CCDC80 in the
vasculature is largely unknown. To analyze the function of
ccdc80 in vivo, we first established a functionally relevant PAH
model using Tg (fli1:EGFP) zebrafish, which express EGFP in
vascular endothelial cells (Lawson and Weinstein, 2002). For
this, we examined the effect of nitric oxide (NO) on the ventral
artery. Treatment of zebrafish with the NO donor SNP dose-
dependently dilated the ventral artery (Supplementary Figure
S1A), and this was significantly attenuated by co-treatment with
KT5823, a specific inhibitor of PKG (Supplementary Figure S1B),
indicating that the effects of NO on the ventral artery diameter
were regulated though PKG. Inhibition of NO synthase with
the specific inhibitor L-NAME significantly decreased the ventral
artery diameter when added alone and reversed the artery dilation
caused by SNP treatment (Figure 3). The length of ventral artery
was not significantly different between the groups. These results
indicate that, like the pulmonary artery in mammals, the ventral
artery in zebrafish is regulated through NO–PKG signaling.
ccdc80 Knockout Increases Ventral
Artery Diameter and Decreases
Expression of col1a1 and edn1 in
Zebrafish
We next determined whether ccdc80 plays a role in controlling
ventral artery diameter in zebrafish. Previous reports have
demonstrated that ccdc80 is expressed in the cardiovascular
system in zebrafish (Brusegan et al., 2012; Della Noce et al.,
2015). Using the CRISPR/Cas9 system (Aida et al., 2015; Kotani
et al., 2015), we knocked out ccdc80 in Tg (fli1:EGFP) zebrafish
(Supplementary Figure S2). When these animals were examined
by fluorescence microscopy, we observed that the ventral artery
diameter in ccdc80-KO zebrafish was significantly larger than that
of control zebrafish (Figure 4A). The length of ventral artery was
not significantly different between the groups, verifying that the
wider diameter of the ventral artery in ccdc80-KO zebrafish was
not related to the length of the ventral artery in the KO group
(Figure 4A).
Because WGCNA identified COL1A1 and SFRP2 in the
CCDC80 network (Figure 2), we compared the whole-body
expression of col1a1 and sfrp2 mRNA in control and ccdc80-
KO zebrafish. As shown in Figure 4B, the expression of col1a1
mRNA was significantly lower in ccdc80-KO animals compared
with the controls, whereas srfp2 mRNA levels were unchanged.
COL1A1 expression is increased by overexpression of EDN1 (Hirt
et al., 2012) and decreased by inhibition of EDN1 synthesis
(Cowling, 2015); therefore, we also measured the effect of ccdc80
deletion on edn1 expression. We found that edn1 mRNA levels
were significantly lower in ccdc80-KO zebrafish compared with
the control animals (Figure 4B). These results suggest that
CCDC80 may regulate the pulmonary artery tone by modulating
endothelin-1-induced collagen expression.
Ccdc80 Expression Is Increased in the
Pulmonary Vascular Lesion in a Rat PAH
Model
To establish the significance of our findings for PAH pathology,
we performed immunohistochemical staining of Ccdc80 protein
in the lung tissues of control rats and rats with PAH caused
by SU5416 and hypoxia. Ccdc80 was not readily detected in
the PAs of control rats (Figures 5A,E), but there was intense
immunoreactivity in the hypertrophied media and adventitia
of the pre-acinar PAs (Figure 5B) and in the thickened
intima, media, and adventitia of the obstructed intra-acinar PAs
(Figure 5F) in the PAH rat. The Ccdc80 immunoreactivity was
localized in the α-SMA–positive cells in the PA media but not in
the intima or adventitia (Figures 5C,G).
DISCUSSION
Involvement of CCDC80, SMAD6, AGR2,
and GZMA in PAH
We demonstrated that expression of CCDC80, SMAD6, AGR2,
and GZMA was significantly dysregulated in two cohorts of
human PAH patients (Mura et al., 2012; Zhao Y. et al., 2014; Zhao
Y.D. et al., 2014) and in three rodent PAH models caused by: (i)
treatment with a VEGF receptor inhibitor under conditions of
hypoxia (Moreno-Vinasco et al., 2008); (ii) overexpression of Fra-
2, a causative gene for systemic sclerosis (Biasin et al., 2014); and
(iii) schistosomiasis (Graham et al., 2013).
CCDC80, which was significantly upregulated in the five PAH
transcriptome datasets, is a 950-amino acid secreted protein
that binds to ECM proteins, including glycosaminoglycans, and
promotes cell adhesion (Manabe et al., 2008). Interestingly,
human steroid-sensitive gene 1 (SSG1), which is identical to the
530-amino acid amino-terminal sequence of human CCDC80
protein, is highly expressed in cardiovascular systems and is
phosphorylated by PKG (Wang et al., 2013). These studies
suggest that CCDC80 may regulate vascular function via the ECM
and PKG signaling. Consistent with this, we demonstrated that
knockout of ccdc80 in zebrafish caused dilation of the ventral
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FIGURE 2 | Networks among the genes dysregulated in PAH identified by WGCNA. The coefficient of variation (CV) of the normalized probe intensity for each
gene in each transcriptome dataset was calculated, and the genes were sorted in descending order by CV. Of the top 3000 genes in each dataset, 40 genes were
common to all five datasets and were subjected to WGCNA. The genes were clustered into three modules and the networks identified in these modules are shown.
CCDC80, AGR2, SMAD6, and GZMA, which were significantly dysregulated in all five PAH transcriptome datasets, are shown in boxes.
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FIGURE 3 | The zebrafish ventral artery diameter is increased by a NO donor and decreased by a NO synthase inhibitor. (A) In vivo imaging of the ventral
artery of Tg (fli1:EGFP) zebrafish at 6 dpf. Zebrafish were incubated with or without 10 mM Sodium nitroprusside (SNP) and/or 10 mM L-NAME for 2 h and then
placed on microscope slides on their backs. The ventral artery was imaged under a fluorescent microscope at 100 frames/s for 5 s. The image stack projections and
time-lapse imaging traces at the level of the ventral artery (dotted lines) are shown. Scale bars, 100 µm. (B) The diameter of the ventral artery was increased and
decreased by zebrafish treatment with SNP and L-NAME, respectively, relative to untreated zebrafish. The ventral artery diameter of zebrafish co-treated with SNP
and L-NAME was not significantly different from that of control zebrafish. The ventral artery diameters were measured using time-lapse imaging. N = 5 for each
group. ∗p < 0.05 vs control. (C) The length of ventral artery in zebrafish treated with SNP and/or L-NAME was not significantly different compared to that in
untreated zebrafish. N = 5 for each group.
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FIGURE 4 | Knockout of ccdc80 causes ventral artery dilation and decreases col1a1 and edn1 expression in zebrafish. (A) In vivo imaging of the ventral
artery of control and ccdc80 knockout Tg (fli1:EGFP) zebrafish at 6 dpf. Zebrafish were placed on slides on their backs, and the ventral artery was imaged under a
fluorescence microscope at 100 frames/s for 5 s. Image stack projections and time-lapse imaging traces at the level of the ventral artery (dotted lines) are shown.
Bar, 100 µm. The ventral artery diameter of the ccdc80 knockout zebrafish was significantly larger than that of control, whereas the length of ventral artery was not
significantly different between groups. The upper right bar graph shows quantification of ventral artery diameters measured using time-lapse imaging. The lower right
bar graph shows quantification of ventral artery lengths. N = 6 or 9 for the control and ccdc80 knockout groups, respectively. ∗p < 0.05 vs. control. (B) qPCR
analysis of col1a1, sfrp2, and edn1 mRNA levels in control and ccdc80 knockout zebrafish at 6 dpf. Expression of col1a1, sfrp2, and edn1 was normalized to that of
gapdh. N = 8 per group. ∗p < 0.05 vs. control groups.
artery and decreased the expression of col1a1. We also found that
pharmacological inhibition of PKG significantly attenuated the
effect of ccdc80 knockout on the zebrafish ventral artery (data not
shown). Collectively, these findings point to a possible role for
CCDC80 in the pathogenesis of PAH (discussed later).
SMAD6, a member of the SMAD family of TGFβ signaling
regulators (Li, 2015), was also downregulated in all five PAH
transcriptome datasets. SMAD6 has been shown to negatively
regulate TGFβ signaling through the TGFβ-activated kinase
(TAK1)–mitogen-activated protein kinase (MAPK) pathway
(Jung et al., 2013). Heterozygous mutations in the type II
receptor for bone morphogenetic protein (BMPR2), which
underlie the majority of the inherited and familial forms
of PAH (Guignabert et al., 2015), stimulate the TGFβ–
TAK1–MAPK pathway (Nasim et al., 2012). These studies
suggest that reduced expression of SMAD6 may increase
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FIGURE 5 | Expression of Ccdc80 is increased in the lungs of rats with PAH. (A–H) Representative photomicrographs of pulmonary arteries (PAs) from control
rats (A and E) or rats with PAH induced by SU5416 /hypoxia (B–D and F–H). Serial cross-sectional views of pre-acinar PA (A–D) and intra-acinar PA (E–H)
immunostained for Ccdc80 and α-smooth muscle actin (α-SMA). Scale bars, 50 µm. Original magnification (×400).
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TGFβ–TAK1–MAPK pathway activity, similar to the effects
of BMPR2 mutation. Because inhibition of the TGFβ–TAK1–
MAPK pathway rescues abnormal proliferation and apoptosis
of pulmonary artery smooth muscle cells isolated from BMPR2
mutant mice (Nasim et al., 2012), normalizing the decrease in
SMAD6 expression may be therapeutic in PAH.
The expression of AGR2 was significantly increased in the
five PAH transcriptome datasets. AGR2 has been proposed
to be involved in development, tissue regeneration, and
cancer metastasis (Brychtova et al., 2011). AGR2 can bind to
α-dystroglycan, which regulates the ECM and interaction with
integrins (Edeleva and Shcherbata, 2013). Thus, the increase
in AGR2 expression may be related to the dysregulated ECM
observed in PAH.
GZMA was significantly downregulated in all five PAH
transcriptome datasets. GZMA is a member of the granzyme
family of proteins, which are important mediators of cell death
induced by immune cells (Hendel et al., 2010). Previous work
has shown that TGFβ decreases GZMA expression and inhibits
its function in cytotoxic T cells (Thomas and Massague, 2005).
Dysregulation of cytotoxic T cells has been reported in PAH
(Ulrich et al., 2008; Savai et al., 2012), raising the possibility that
the decrease in GZMA expression in PAH may be related to the
dysregulation of cytotoxic T cells.
In addition to these observations, the expression levels and/or
activities of CCDC80, AGR2, and GZMA in human plasma have
been related to various pathological states (Accardo-Palumbo
et al., 2010; Kani et al., 2013; Menni et al., 2015). It may therefore
be worthwhile to perform similar measurements of these proteins
in the plasma of human PAH patients and determine whether
their levels and/or activities correlate with the clinical stages
of PAH.
CCDC80 May Regulate Vascular Tone by
Modulating Endothelin-1–induced
Collagen Expression
In this study, we demonstrated that knockout of ccdc80 in
zebrafish caused dilation of the ventral artery and decreased the
expression of both edn1 and col1a1. We also showed that Ccdc80
immunoreactivity was increased in the hypertrophied media and
adventitia of the pre-acinar PAs and in the thickened intima,
media, and adventitia of the obstructed intra-acinar PAs in a rat
PAH model.
The expression of CCDC80 was correlated with fibrillin-1
whose expression is induced by TGFβ (Summers et al.,
2010), suggesting that it may be induced by TGFβ signaling.
TGFβ signaling is activated in familial PAH caused by
mutation of BMPR2 and in syndromic PAH caused by
systemic sclerosis or schistosomiasis (Varga and Pasche, 2009;
Aschner and Downey, 2016). In various models, PAH is
ameliorated by blockade of TGFβ signaling through diverse
mechanisms, including administration of neutralizing antibodies,
antisense nucleotides, or TGFβ receptor kinase inhibitors, and
by gene transfer of inhibitory SMAD (Varga and Pasche,
2009; Aschner and Downey, 2016). TGFβ signaling regulates
vascular tone, including that of PAs, by regulating the
expression of vasodilators such as NO and vasoconstrictors
such as endothelin-1 (Pardali and ten Dijke, 2012). These
studies suggest that expression of CCDC80 may positively
correlate with TGFβ signaling, leading to decreased NO and
increased endothelin-1 levels. Further studies using both in vitro
and in vivo approaches are required to fully elucidate the
functions of CCDC80 in the pathophysiology of PAH and to
examine its potential as a marker and/or a therapeutic target
in PAH.
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